Natco Pharma
Natco Pharma Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of generic and specialty medicines. Founded in 1981, the company has achieved significant milestones, including the launch of several high-quality generic formulations and active pharmaceutical ingredients (APIs) that cater to various therapeutic areas such as oncology, cardiology, and neurology. With a strong presence in both domestic and international markets, Natco Pharma is recognised for its commitment to innovation and affordability. The company’s core products, including complex generics and biosimilars, stand out due to their quality and accessibility. Natco's strategic focus on research and development has positioned it as a leader in the pharmaceutical sector, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Natco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Natco Pharma's score of 17 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Natco Pharma's reported carbon emissions
In 2023, Natco Pharma reported total carbon emissions of approximately 68,760,000 kg CO2e, comprising 20,898,100 kg CO2e from Scope 1 and 39,945,230 kg CO2e from Scope 2 emissions. Notably, Scope 3 emissions were significant, amounting to 62,668,710 kg CO2e, primarily driven by purchased goods and services, which accounted for 18,426,000 kg CO2e. In 2022, the company recorded total emissions of about 48,000,000 kg CO2e, with Scope 1 emissions at 13,477,000 kg CO2e and Scope 2 emissions at 44,967,000 kg CO2e. The previous year, 2021, saw total emissions of approximately 26,000,000 kg CO2e, with Scope 1 at 13,265,000 kg CO2e and Scope 2 at 44,696,000 kg CO2e. Despite these figures, Natco Pharma has not publicly committed to specific reduction targets or initiatives, indicating a potential area for improvement in their climate strategy. The company’s emissions per rupee of turnover have shown a decreasing trend, with 2023 reporting 0.00245 kg CO2e per rupee, down from 0.003455 kg CO2e in 2022. This suggests a commitment to improving efficiency, although further concrete climate commitments would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,265,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 44,696,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Natco Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
